Axon Enterprise - AXON Stock Forecast, Price & News

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Axon Enterprise in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" AXON shares.
View AXON analyst ratings or view top-rated stocks.

7 Wall Street research analysts have issued twelve-month price objectives for Axon Enterprise's shares. Their AXON share price forecasts range from $130.00 to $200.00. On average, they predict the company's share price to reach $168.25 in the next year. This suggests that the stock has a possible downside of 10.5%.
View analysts price targets for AXON or view top-rated stocks among Wall Street analysts.

Axon Enterprise's stock was trading at $157.00 at the start of the year. Since then, AXON shares have increased by 19.7% and is now trading at $187.92.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, February 23rd 2023.
View our AXON earnings forecast.

Axon Enterprise, Inc. (NASDAQ:AXON) issued its earnings results on Monday, November, 15th. The biotechnology company reported $1.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.26 by $0.91. The biotechnology company had revenue of $231.99 million for the quarter, compared to analysts' expectations of $201.11 million. Axon Enterprise had a trailing twelve-month return on equity of 9.88% and a net margin of 9.75%. The business's quarterly revenue was up 39.4% compared to the same quarter last year. During the same quarter last year, the business earned ($0.01) earnings per share.

Axon Enterprise issued an update on its FY 2022 earnings guidance on Tuesday, November, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.15 billion-$1.16 billion, compared to the consensus revenue estimate of $1.11 billion.

Based on aggregate information from My MarketBeat watchlists, some companies that other Axon Enterprise investors own include Novavax (NVAX), NVIDIA (NVDA), Netflix (NFLX), Alibaba Group (BABA), Micron Technology (MU), TherapeuticsMD (TXMD), ACADIA Pharmaceuticals (ACAD), bluebird bio (BLUE) and Arena Pharmaceuticals (ARNA).

(AXON) raised $251 million in an initial public offering (IPO) on Thursday, June 11th 2015. The company issued 17,900,000 shares at a price of $13.00-$15.00 per share. Jefferies, Evercore ISI and RBC Capital Markets served as the underwriters for the IPO and JMP Securities and Baird were co-managers.

Axon Enterprise trades on the NASDAQ under the ticker symbol "AXON."

Axon Enterprise's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (10.28%), Vanguard Group Inc. (8.80%), Baillie Gifford & Co. (3.72%), State Street Corp (3.05%), Alliancebernstein L.P. (2.40%) and Conestoga Capital Advisors LLC (1.38%). Insiders that own company stock include Adriane M Brown, Caitlin Elizabeth Kalinowski, Hadi Partovi, Jawad A Ahsan, Jeffrey C Kunins, Joshua Isner, Julie A Cullivan, Luke Larson, Mark W Kroll, Matthew R Mcbrady, Matthew R Mcbrady and Patrick W Smith.
View institutional ownership trends.

Shares of AXON stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AXON stock can currently be purchased for approximately $187.92.

Axon Enterprise (NASDAQ:AXON) has a market capitalization of $13.37 billion and generates $863.38 million in revenue each year. The biotechnology company earns $-60,020,000.00 in net income (profit) each year or $1.45 on an earnings per share basis.

The company employs 2,992 workers across the globe.

Axon Enterprise's mailing address is 20-22 BEDFORD ROW, LONDON X0, WC1R 4JS. The official website for the company is www.axovant.com. The biotechnology company can be reached via phone at (480) 991-0797, via email at ir@axon.com, or via fax at 480-991-0791.